Efficacy News and Research

RSS

Greenhouse-grown corn seeds could help treat lysosomal storage disease

The seeds of greenhouse-grown corn could hold the key to treating a rare, life-threatening childhood genetic disease, according to researchers from Simon Fraser University.

24 Sep 2012

NCI awards Provocative Questions grant to Mount Sinai School of Medicine researchers

Two Mount Sinai School of Medicine researchers are among a select group of scientists from around the world who have been recognized by the National Cancer Institute (NCI) for their quest to answer the most pressing questions about cancer. Stuart Aaronson, MD, Professor and Chair of Oncological Sciences and Ross Cagan, PhD, Professor of Oncological Sciences at Mount Sinai, have received the NCI's new "Provocative Questions" grant, which was established to explore the important yet less obvious questions about cancer that may have been neglected in this era of significant discovery.

21 Sep 2012

Case Western Reserve researcher to identify mechanistic link between psoriasis and CVD

Armed with a new $1.8 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, dermatology researcher Nicole Ward, PhD, assistant professor of dermatology and neurosciences at Case Western Reserve School of Medicine, will lead a study examining the link between psoriasis and heart attack and stroke.

21 Sep 2012

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Medivir AB, announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.

21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

21 Sep 2012

Antiwasting supplements provide moderate improvements in child health

Study results show that ready-to-use supplementary food, provided to children at risk for malnutrition as part of a general food distribution program, does not significantly improve child weight.

20 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).

20 Sep 2012

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company's second pipeline product.

20 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

Reduced-intensity benefits confirmed for AML cell transplantation

Reduced-intensity conditioning reduces toxicity associated with allogeneic hematopoietic cell transplantation for acute myeloid leukemia without affecting long-term outcomes, show results from the first randomized trial of this treatment.

19 Sep 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Xenex's pulsed xenon UV more effective than bleach in decontaminating C. diff surfaces

Healthcare associated infections (also referred to as HAIs or hospital acquired infections) are the fourth leading cause of death in the United States, costing more than $30 billion each year. Evidence continues to mount that hospital cleanliness plays a role in the spread of HAIs, which are caused by deadly pathogens such as C. diff, MRSA, VRE and Acinetobacter.

19 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Immune Targeting Systems Limited, an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company's lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus.

18 Sep 2012

Sentara Heart Hospital performs first innovative Atrial Fibrillation procedure

Sentara Heart Hospital is leading the way in an innovative Atrial Fibrillation (AF) procedure for what is typically the most difficult to treat or persistent, forms of AF. This past week, surgeons and cardiologists at Sentara Heart Hospital were the first in the world to begin performing surgeries in the Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study (Staged DEEP) feasibility trial.

18 Sep 2012

Pertussis immunity wanes in the 5 years after DTaP vaccination

The risk for pertussis infection in children who receive the combined diphtheria, tetanus, and acellular pertussis vaccine increases by an average of 42% per year after the last dose, a US study shows.

17 Sep 2012

Antimuscarinics only moderately effective for overactive bladder

A comprehensive review of oral antimuscarinics for the treatment of overactive bladder concludes that the efficacy of treatment is, at best, moderate.

17 Sep 2012

Nanoparticles for non-invasive photodynamic therapy of deep cancer

National University of Singapore researchers at the Faculty of Engineering's Department of Bioengineering have discovered a new technology that paves the way for a new safe and non-invasive method of treating deep cancer. Led by Associate Professor Zhang Yong, the team has so far, proven that their technology could inhibit tumour growth and control gene expression in mice. This is a world's first for the use of nanoparticles for non-invasive photodynamic therapy of deep cancer.

17 Sep 2012

Efficacy News and Research

Greenhouse-grown corn seeds could help treat lysosomal storage disease

NCI awards Provocative Questions grant to Mount Sinai School of Medicine researchers

Case Western Reserve researcher to identify mechanistic link between psoriasis and CVD

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Antiwasting supplements provide moderate improvements in child health

Boehringer Ingelheim files MAA with EMA for afatinib approval

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

Reduced-intensity benefits confirmed for AML cell transplantation

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Xenex's pulsed xenon UV more effective than bleach in decontaminating C. diff surfaces

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Sentara Heart Hospital performs first innovative Atrial Fibrillation procedure

Pertussis immunity wanes in the 5 years after DTaP vaccination

Antimuscarinics only moderately effective for overactive bladder

Nanoparticles for non-invasive photodynamic therapy of deep cancer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News